WASHINGTON, Oct 18 (Reuters) - Novo Nordisk A/S’s new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.
The panel voted 16-0 with one abstention in favor of the drug being approved. It would compete with others in a class known as glucagon-like peptide-1 (GLP-1) analogs, which imitate an intestinal hormone that stimulates the production of insulin.
The FDA typically follows the recommendations of its advisors. (Reporting by Toni Clarke; Editing by Sandra Maler)